To our greatest regret CiMaas has filed for bankruptcy, which became effective Tuesday June 11, 2024. Although CiMaas has great assets in the field of NK cell immunotherapy for cancer using its proprietary feeder cell technology and expansion methodology, it was unable to raise enough financial resources to perform the required clinical studies. 

The management team of CiMaas remains dedicated to help patients suffering from cancer and continue to strive for an effective therapy with minimal side-effects.

Strengthened by excellent reviews by international third parties we are working on next steps. We will focus on GMP grade NK cells produced by our GMP grade feeder cells, for which a patent application was recently positively evaluated. We will still aim to make the feeder cells and NK cells available to all interested. 

Please contact us for further information at